JP2005500304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500304A5 JP2005500304A5 JP2003506470A JP2003506470A JP2005500304A5 JP 2005500304 A5 JP2005500304 A5 JP 2005500304A5 JP 2003506470 A JP2003506470 A JP 2003506470A JP 2003506470 A JP2003506470 A JP 2003506470A JP 2005500304 A5 JP2005500304 A5 JP 2005500304A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- protein
- antibody
- particle
- spherical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 100
- 108091007433 antigens Proteins 0.000 claims 100
- 102000036639 antigens Human genes 0.000 claims 100
- 239000002245 particle Substances 0.000 claims 93
- 102000034238 globular proteins Human genes 0.000 claims 83
- 108091005896 globular proteins Proteins 0.000 claims 83
- 108090000623 proteins and genes Proteins 0.000 claims 39
- 235000018102 proteins Nutrition 0.000 claims 38
- 102000004169 proteins and genes Human genes 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 37
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 238000002405 diagnostic procedure Methods 0.000 claims 15
- 239000000243 solution Substances 0.000 claims 11
- 238000009007 Diagnostic Kit Methods 0.000 claims 10
- 239000000725 suspension Substances 0.000 claims 10
- 230000004071 biological effect Effects 0.000 claims 9
- 241000701022 Cytomegalovirus Species 0.000 claims 8
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 8
- 241000711549 Hepacivirus C Species 0.000 claims 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 8
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 230000003612 virological effect Effects 0.000 claims 8
- 235000004252 protein component Nutrition 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 5
- 239000002159 nanocrystal Substances 0.000 claims 5
- 241000709687 Coxsackievirus Species 0.000 claims 4
- 241000709661 Enterovirus Species 0.000 claims 4
- 241000991587 Enterovirus C Species 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 4
- 241000701806 Human papillomavirus Species 0.000 claims 4
- 208000000389 T-cell leukemia Diseases 0.000 claims 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 108091061980 Spherical nucleic acid Proteins 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 238000002983 circular dichroism Methods 0.000 claims 3
- 239000011246 composite particle Substances 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 239000012460 protein solution Substances 0.000 claims 3
- 108010088751 Albumins Chemical class 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 229920002678 cellulose Chemical class 0.000 claims 2
- 239000001913 cellulose Chemical class 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 238000004611 spectroscopical analysis Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Chemical class 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 230000003622 anti-hsv Effects 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 239000012148 binding buffer Substances 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- ZTUGCJNAJJDKDC-UHFFFAOYSA-N n-(3-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCO ZTUGCJNAJJDKDC-UHFFFAOYSA-N 0.000 claims 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000000962 organic group Chemical group 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000117 poly(dioxanone) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000011363 radioimmunotherapy Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29998901P | 2001-06-21 | 2001-06-21 | |
| PCT/US2002/019870 WO2003000014A2 (en) | 2001-06-21 | 2002-06-21 | Spherical protein particles and methods of making and using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500304A JP2005500304A (ja) | 2005-01-06 |
| JP2005500304A5 true JP2005500304A5 (cg-RX-API-DMAC7.html) | 2005-11-17 |
Family
ID=23157185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506470A Pending JP2005500304A (ja) | 2001-06-21 | 2002-06-21 | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7998477B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1492554B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005500304A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002322295C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2451185A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL159475A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ530700A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003000014A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030074693A (ko) * | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| NZ530700A (en) | 2001-06-21 | 2009-02-28 | Altus Pharmaceuticals Inc | Spherical protein particles and methods of making and using them |
| JP4161101B2 (ja) * | 2002-06-21 | 2008-10-08 | 独立行政法人 日本原子力研究開発機構 | 生体高分子の結晶育成装置 |
| BRPI0412735A (pt) | 2003-07-18 | 2006-09-26 | Baxter Int | métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada |
| JP2005241389A (ja) * | 2004-02-25 | 2005-09-08 | Ochiyanomizu Jiyoshi Univ | 蛍光標識糖鎖の特異的固定化試薬および固定化方法 |
| MXPA06012992A (es) | 2004-05-12 | 2007-02-12 | Baxter Int | Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente. |
| EP1765294B1 (en) | 2004-05-12 | 2008-09-24 | Baxter International Inc. | Nucleic acid microspheres, production and delivery thereof |
| CA2566199C (en) | 2004-05-12 | 2013-10-22 | Baxter International Inc. | Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
| US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| AU2005299716B2 (en) | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| US7956160B2 (en) * | 2005-07-22 | 2011-06-07 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
| EP1948259B1 (en) * | 2005-10-26 | 2017-03-22 | Genesis Technologies Limited | Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products |
| WO2007072982A1 (en) * | 2005-12-20 | 2007-06-28 | Fujifilm Corporation | Protein nanoparticles and the use of the same |
| US20090280148A1 (en) | 2006-03-29 | 2009-11-12 | Makiko Aimi | Casein nanoparticle |
| CN101500616A (zh) | 2006-08-04 | 2009-08-05 | 巴克斯特国际公司 | 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物 |
| WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
| CN101686939B (zh) | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| JP2008285432A (ja) | 2007-05-16 | 2008-11-27 | Fujifilm Corp | 皮膚外用剤 |
| CA2691531C (en) | 2007-06-22 | 2016-11-01 | Board Of Regents,The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| WO2009005709A1 (en) * | 2007-06-28 | 2009-01-08 | Surmodics, Inc. | Polypeptide microparticles |
| US20090022805A1 (en) * | 2007-06-28 | 2009-01-22 | Joram Slager | Polypeptide microparticles having sustained release characteristics, methods and uses |
| KR100845009B1 (ko) * | 2007-08-07 | 2008-07-08 | 한국생명공학연구원 | 전하를 띠는 물질이 고착된 다공성 고분자 입자 및 그제조방법 |
| WO2010005726A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| US8323615B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
| US8367427B2 (en) | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8323685B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| EP2376522A4 (en) * | 2008-11-16 | 2013-12-25 | Univ Texas | LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS |
| FR2938542B1 (fr) | 2008-11-18 | 2013-06-14 | Sang Bourgogne Franche Comte Ets Franc | Proteine cd20 tronquee, deltacd20 |
| US8563041B2 (en) * | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| US8529933B2 (en) | 2009-07-27 | 2013-09-10 | Warsaw Orthopedic, Inc. | Biphasic calcium phosphate cement for drug delivery |
| JP5491119B2 (ja) | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| DK2509634T3 (en) | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| US20120309016A1 (en) * | 2010-02-11 | 2012-12-06 | Hoffmann-La Roche Inc. | 3d adcc nk facs assay |
| WO2013067281A1 (en) * | 2011-11-04 | 2013-05-10 | Battelle Memorial Institute | Processes for producing protein microparticles |
| ES2985784T3 (es) | 2011-11-18 | 2024-11-07 | Regeneron Pharma | Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| US20150177115A1 (en) | 2012-04-06 | 2015-06-25 | Slingshot Biosciences | Hydrogel particles with tunable optical properties |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| WO2014043618A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Process for preparing therapeutic nanoparticles |
| CN104870019A (zh) | 2012-11-27 | 2015-08-26 | 阿特根公司 | 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN103018446B (zh) * | 2012-12-24 | 2014-08-20 | 青岛汉唐生物科技有限公司 | 用于检测甲型肝炎病毒抗体的方法、检测用的试剂盒及其制备方法 |
| MX2016002485A (es) * | 2013-08-26 | 2016-11-14 | Ps Therapies Ltd | Composiciones y metodos para el tratamiento de condiciones nasales. |
| US20160228371A1 (en) * | 2013-10-18 | 2016-08-11 | Abbvie Inc. | Stable solid units and methods of making the same |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| WO2016010081A1 (ja) | 2014-07-18 | 2016-01-21 | 一般財団法人化学及血清療法研究所 | ウイルス様粒子を含むワクチン |
| EP3179985A1 (en) * | 2014-08-14 | 2017-06-21 | Brown University | Compositions for stabilizing and delivering proteins |
| US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
| JP6692834B2 (ja) | 2015-02-09 | 2020-05-13 | スリングショット バイオサイエンシーズ， インコーポレイテッド | 調整可能な光学特性を有するヒドロゲル粒子およびその使用の方法 |
| AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| AU2016252393A1 (en) * | 2015-04-24 | 2017-11-09 | Colgate-Palmolive Company | Porous protein particles as carriers for actives |
| EP3324174A4 (en) * | 2015-07-13 | 2019-03-06 | Sony Corporation | PROCESS FOR IMPROVING LIGHT EMISSION, METHOD FOR DETECTING SUBSTANCES, DEVICE FOR DETECTING SUBSTANCES AND LIGHT EMISSION AMPLIFIERS |
| EP3502142B1 (en) | 2016-06-22 | 2021-10-27 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Bispecific antibody and antibody conjugate for tumour therapy and use thereof |
| CN108504638B (zh) * | 2017-02-28 | 2021-09-17 | 中国科学院过程工程研究所 | 一种口蹄疫灭活病毒抗原纯化或储存的方法 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| CN113238039B (zh) * | 2018-03-07 | 2023-03-31 | 深圳市伯劳特生物制品有限公司 | 一种检测试剂盒 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| US20200206132A1 (en) * | 2018-12-31 | 2020-07-02 | Incube Labs, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10993459B2 (en) | 2019-09-23 | 2021-05-04 | Ralph Yoder | Method for unlocking bioactive proteins |
| CA3158119A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| KR20220129585A (ko) | 2020-01-24 | 2022-09-23 | 슬링샷 바이오사이언시즈 인코포레이티드 | 세포-유사 보정 입자를 위한 조성물 및 방법 |
| WO2021177996A1 (en) * | 2020-03-02 | 2021-09-10 | Northwestern University | Fit-flares for detection of intracellular analytes in live cells |
| JP7807395B2 (ja) | 2020-05-04 | 2026-01-27 | スリングショット バイオサイエンシーズ， インコーポレイテッド | 多重化アッセイのためのパッシブ光学バーコード付与のための組成物および方法 |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| AU2022376541A1 (en) | 2021-10-29 | 2024-04-18 | Slingshot Biosciences, Inc. | Hydrogel particles as feeder cells and as synthetic antigen presenting cells |
| CN114460301B (zh) * | 2021-12-28 | 2024-11-29 | 上海睿康生物科技有限公司 | 一种测定血清中肌酸激酶同工酶含量的检测试剂盒 |
| CN119907921A (zh) | 2022-05-05 | 2025-04-29 | 弹弓生物科学公司 | 用于血液学的作为红细胞模拟物的工程化颗粒和含有工程化颗粒的组合物 |
| CA3257621A1 (en) | 2022-06-02 | 2023-12-07 | Slingshot Biosciences, Inc. | APOPTOTIC CELL MIMETIC |
| CN120712108A (zh) | 2022-10-26 | 2025-09-26 | 弹弓生物科学公司 | 具有可调整光学性质的大小可调整合成颗粒和用于使用其进行免疫细胞激活的方法 |
| WO2025049609A1 (en) | 2023-08-29 | 2025-03-06 | Slingshot Biosciences, Inc. | Cd34 stem cell mimics |
| CN119925588B (zh) * | 2025-04-08 | 2025-07-01 | 北京华诺泰生物医药科技有限公司 | 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4334024A (en) | 1980-11-03 | 1982-06-08 | Sarjit Johal | Preparation and crystallization of fraction I protein from plant sources |
| DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| DE3419782C1 (de) | 1984-05-26 | 1985-11-14 | Gödecke AG, 1000 Berlin | Sphaerische Proteinpartikel mit immunadsorbierenden Eigenschaften und Verfahren zu deren Herstellung |
| US6727278B1 (en) * | 1986-08-27 | 2004-04-27 | Dms Pharmaceutical Inc. | Pharmaceutically active agents that impede amyloid formation in vivo |
| DE69004101T2 (de) | 1989-12-21 | 1994-03-24 | Novonordisk As | Verfahren zur kristallisation von enzymen. |
| US5780599A (en) | 1990-07-13 | 1998-07-14 | Novo Nordisk A/S | Growth hormone crystals and a process for production of growth hormone crystals |
| US5618710A (en) | 1990-08-03 | 1997-04-08 | Vertex Pharmaceuticals, Inc. | Crosslinked enzyme crystals |
| US6063910A (en) * | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| US5751453A (en) * | 1991-12-06 | 1998-05-12 | Ncr Corporation | Liquid crystal display with pen-input capability |
| WO1994010980A1 (en) * | 1992-11-16 | 1994-05-26 | Corporation Of Mercer University | Compositions using microencapsulated neutralizing antibodies |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| WO1997008300A1 (en) | 1995-08-30 | 1997-03-06 | Ariad Pharmaceuticals, Inc. | Crystalline zap family proteins |
| US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| US5932212A (en) | 1996-05-24 | 1999-08-03 | Altus Biologics, Inc. | Crosslinked protein crystal formulations and their use as catalysts in organic solvents |
| US6652837B1 (en) * | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| US6140475A (en) | 1997-04-11 | 2000-10-31 | Altus Biologics Inc. | Controlled dissolution crosslinked protein crystals |
| WO1999055310A1 (en) * | 1998-04-27 | 1999-11-04 | Altus Biologics Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
| US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| CA2361507C (en) | 1999-03-05 | 2014-05-06 | Genencor International, Inc. | Method for rapidly obtaining crystals with desirable morphologies |
| HK1049621A1 (zh) * | 1999-06-09 | 2003-05-23 | 罗伯特‧E‧希弗斯 | 超临界流体辅助的喷雾和鼓泡乾燥 |
| DE20023081U1 (de) | 1999-06-10 | 2003-01-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 80539 München | Eingekapselte Kristalle mit Mehrlagenbeschichtung |
| GB9915975D0 (en) * | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| FR2802445B1 (fr) * | 1999-12-15 | 2002-02-15 | Separex Sa | Procede et dispositif de captage de fines particules par piegeage au sein d'un melange solide de type neige carbonique |
| US6562952B1 (en) * | 2000-10-31 | 2003-05-13 | The University Of Kansas | Precipitation of proteins from organic solutions |
| US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
| EP1801123A3 (en) * | 2000-12-28 | 2007-11-21 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| KR20030074693A (ko) * | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| NZ530700A (en) | 2001-06-21 | 2009-02-28 | Altus Pharmaceuticals Inc | Spherical protein particles and methods of making and using them |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
-
2002
- 2002-06-21 NZ NZ530700A patent/NZ530700A/en not_active IP Right Cessation
- 2002-06-21 EP EP02756275.0A patent/EP1492554B1/en not_active Expired - Lifetime
- 2002-06-21 IL IL15947502A patent/IL159475A0/xx unknown
- 2002-06-21 AU AU2002322295A patent/AU2002322295C1/en not_active Ceased
- 2002-06-21 WO PCT/US2002/019870 patent/WO2003000014A2/en not_active Ceased
- 2002-06-21 CA CA002451185A patent/CA2451185A1/en not_active Abandoned
- 2002-06-21 JP JP2003506470A patent/JP2005500304A/ja active Pending
-
2003
- 2003-12-19 US US10/741,861 patent/US7998477B2/en not_active Expired - Fee Related
-
2011
- 2011-07-27 US US13/192,345 patent/US20120282464A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005500304A5 (cg-RX-API-DMAC7.html) | ||
| AU2002322295C1 (en) | Spherical protein particles and methods of making and using them | |
| RU2442571C2 (ru) | Кристаллизация антител или их фрагментов | |
| Akash et al. | Development of therapeutic proteins: advances and challenges | |
| CN102753147B (zh) | 长效红细胞生成素缀合物的液体制剂 | |
| AU2002322295A1 (en) | Spherical protein particles and methods of making and using them | |
| JP2018535650A (ja) | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 | |
| JPH04505010A (ja) | 免疫調節障害の処置のための薬剤生成物 | |
| KR20160062760A (ko) | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 | |
| JPH06502410A (ja) | 二特異的試薬を用いた標的免疫化 | |
| KR20160062761A (ko) | 키메라 항원 수용체 t 세포 스위치 및 이의 용도 | |
| JPH0717519B2 (ja) | α―インターフェロンに対する抗体と複合されたα―インターフェロン治療製剤 | |
| TW201223541A (en) | Liquid formulations of long acting interferon alpha conjugate | |
| JP2001513335A (ja) | 細胞内の物質移送のための抗体から誘導されたベクター | |
| JP2004534513A5 (cg-RX-API-DMAC7.html) | ||
| WO2018121578A1 (zh) | 稳定的包含cd147单克隆抗体的药物制剂 | |
| US20250295590A1 (en) | Fabrication of protein-encapsulating microgels | |
| US20170051058A1 (en) | Immunostimulatory anti-ceacam1 antibody | |
| JP2019536756A (ja) | Ｉｌ−２３ａ抗体を用いて疾患を処置する方法 | |
| Tite et al. | Inverse Ir gene control of the antibody and T cell proliferative responses to human basement membrane collagen. | |
| EP0707473A1 (en) | Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads | |
| JP2004514423A5 (cg-RX-API-DMAC7.html) | ||
| CN101177453B (zh) | 抗人肿瘤坏死因子α的重组嵌合抗体 | |
| WO2022048494A1 (en) | Anti-sars-cov-2 neutralizing antibodies | |
| CN115569191A (zh) | 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂 |